Jupiter Neurosciences, Inc. Common Stock (JUNS) - Total Liabilities
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has total liabilities worth $4.08 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Jupiter Neurosciences, Inc. Common Stock (JUNS) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Jupiter Neurosciences, Inc. Common Stock - Total Liabilities Trend (2019–2025)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Jupiter Neurosciences, Inc. Common Stock assets under control.
Jupiter Neurosciences, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EMU NL
AU:EMU
|
Australia | AU$473.02K |
|
AM Resources Corp
V:AMR
|
Canada | CA$1.11 Million |
|
The GYM Group PLC
LSE:GYM
|
UK | GBX474.20 Million |
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
Germany | €480.38K |
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
USA | $1.46 Million |
|
Wi2Wi Corporation
V:YTY
|
Canada | CA$5.74 Million |
|
Oriental Trimex Limited
NSE:ORIENTALTL
|
India | Rs381.79 Million |
|
Odyssean Investment Trust PLC
LSE:OIT
|
UK | GBX1.34 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Jupiter Neurosciences, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See JUNS net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jupiter Neurosciences, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jupiter Neurosciences, Inc. Common Stock (2019–2025)
The table below shows the annual total liabilities of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.40 Million | +264.26% |
| 2024-12-31 | $2.03 Million | -65.88% |
| 2023-12-31 | $5.95 Million | -19.38% |
| 2022-12-31 | $7.38 Million | +26.26% |
| 2021-12-31 | $5.85 Million | +37.18% |
| 2020-12-31 | $4.26 Million | -15.16% |
| 2019-12-31 | $5.02 Million | -- |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinic… Read more